Administration Logistics and G-CSF Prophylaxis in ES-SCLC

Dr. Leal discusses practical logistics of lurbinectedin plus atezolizumab, administered together every 21 days. She incorporates maintenance discussions into initial treatment planning, particularly important for patients traveling long distances with caregivers. Most patients with ports prefer intravenous administration despite subcutaneous atezolizumab being an option with comparable efficacy, safety, and drug levels but shorter infusion time.

For patients already established on intravenous regimens throughout induction, she typically continues intravenous administration rather than switching formulations, though subcutaneous options may benefit patients on monotherapy for other indications.

Dr. Sands addresses G-CSF prophylaxis, which was mandated in the IMforte trial given that patients have already experienced bone marrow suppression from induction chemotherapy. He considers prophylactic G-CSF straightforward and standard practice, consistent with management approaches for other myelosuppressive regimens.

Dr. Shields notes she uses trilaciclib during induction to prevent lineage suppression and neutropenia but follows label directions requiring mandatory G-CSF for every maintenance cycle when transitioning to lurbinectedin plus atezolizumab. She expresses interest in potentially incorporating myeloprotective strategies earlier in treatment given increasingly aggressive maintenance approaches, acknowledging this represents an evolution in her practice given the new enhanced maintenance landscape requiring more comprehensive supportive care planning from treatment initiation.